Shoaib Ugradar

1.4k total citations
65 papers, 764 citations indexed

About

Shoaib Ugradar is a scholar working on Pathology and Forensic Medicine, Neurology and Dermatology. According to data from OpenAlex, Shoaib Ugradar has authored 65 papers receiving a total of 764 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pathology and Forensic Medicine, 32 papers in Neurology and 23 papers in Dermatology. Recurrent topics in Shoaib Ugradar's work include Ophthalmology and Eye Disorders (40 papers), Facial Rejuvenation and Surgery Techniques (20 papers) and Cerebral Venous Sinus Thrombosis (20 papers). Shoaib Ugradar is often cited by papers focused on Ophthalmology and Eye Disorders (40 papers), Facial Rejuvenation and Surgery Techniques (20 papers) and Cerebral Venous Sinus Thrombosis (20 papers). Shoaib Ugradar collaborates with scholars based in United States, United Kingdom and Germany. Shoaib Ugradar's co-authors include Raymond S. Douglas, Daniel B. Rootman, Robert A. Goldberg, Rona Z. Silkiss, Ariel M. Azhdam, Kimberly Cockerham, George J. Kahaly, Tünde Mester, Tatyana Milman and Andrea L. Kossler and has published in prestigious journals such as SHILAP Revista de lepidopterología, Endocrine Reviews and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Shoaib Ugradar

61 papers receiving 732 citations

Peers

Shoaib Ugradar

PFM

NEURO

OPHTH

EDM

DERMA

Onur Konuk Türkiye

Janet M. Neigel Canada

Peter S. Levin United States

Y.O. Grusha Russia

Kyle J. Godfrey United States

Shine C. S. Kao Taiwan

L Levin United States

Andrew G. Lee United States

Robert B. Wilkins United States

James A. Rush United States

Onur Konuk Türkiye

Shoaib Ugradar

371 ×0.8

PFM

173 ×0.5

NEURO

326 ×1.2

OPHTH

195 ×0.8

EDM

50 ×0.2

DERMA

Citations per year, relative to Shoaib Ugradar Shoaib Ugradar (= 1×) peers Onur Konuk

Countries citing papers authored by Shoaib Ugradar

Since Specialization

Citations

This map shows the geographic impact of Shoaib Ugradar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shoaib Ugradar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shoaib Ugradar more than expected).

Fields of papers citing papers by Shoaib Ugradar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shoaib Ugradar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shoaib Ugradar. The network helps show where Shoaib Ugradar may publish in the future.

Co-authorship network of co-authors of Shoaib Ugradar

This figure shows the co-authorship network connecting the top 25 collaborators of Shoaib Ugradar. A scholar is included among the top collaborators of Shoaib Ugradar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shoaib Ugradar. Shoaib Ugradar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ugradar, Shoaib, et al.. (2025). The Use of Biologics for Thyroid Eye Disease. BioDrugs. 39(4). 607–619.

Ugradar, Shoaib, et al.. (2024). The Rate of Re-treatment in Patients Treated with Teprotumumab. Ophthalmology. 132(1). 92–97. 9 indexed citations

Ugradar, Shoaib, et al.. (2024). Clinical and Radiologic Predictors of Response to Teprotumumab: A 3D Volumetric Analysis of 35 Patients. Ophthalmic Plastic and Reconstructive Surgery. 41(4). 408–414. 2 indexed citations

Ugradar, Shoaib, et al.. (2024). 12318 Preliminary Safety and Efficacy of Subcutaneous Lonigutamab (anti-IGF-1R) from a Phase 1/2 Proof of Concept Study in Patients with Thyroid Eye Disease. Journal of the Endocrine Society. 8(Supplement_1). 2 indexed citations

Ugradar, Shoaib, et al.. (2024). Teprotumumab for the Treatment of Thyroid Eye Disease. Endocrine Reviews. 45(6). 843–857. 5 indexed citations

Ugradar, Shoaib, et al.. (2024). Teprotumumab for thyroid eye disease in patients with hypothyroid/euthyroid state: a multicenter case series. Graefe s Archive for Clinical and Experimental Ophthalmology. 263(1). 225–230. 1 indexed citations

Ugradar, Shoaib, et al.. (2023). The effects of topical oxymetazoline on eyelid position, eye redness, and patient-reported eye appearance: A randomized controlled trial. Journal of Plastic Reconstructive & Aesthetic Surgery. 80. 66–74. 4 indexed citations

Douglas, Raymond S., Steven M. Couch, Sara T. Wester, et al.. (2023). Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity. The Journal of Clinical Endocrinology & Metabolism. 109(1). 25–35. 39 indexed citations

Douglas, Raymond S., Andrea L. Kossler, César A. Briceño, et al.. (2022). Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach. Journal of Neuro-Ophthalmology. 42(3). 334–339. 10 indexed citations

10.

Douglas, Raymond S., Roger A. Dailey, Prem S. Subramanian, et al.. (2022). Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease. JAMA Ophthalmology. 140(4). 328–328. 43 indexed citations

11.

Wang, Yao, Tünde Mester, Shoaib Ugradar, & Raymond S. Douglas. (2021). Teprotumumab for the treatment of thyroid eye disease: Clinical experience from expanded access program (EAP). Investigative Ophthalmology & Visual Science. 62(8). 3339–3339. 2 indexed citations

12.

Ugradar, Shoaib, Yao Wang, Tünde Mester, George J. Kahaly, & Raymond S. Douglas. (2021). Improvement of asymmetric thyroid eye disease with teprotumumab. British Journal of Ophthalmology. 106(6). 755–759. 16 indexed citations

13.

Silkiss, Rona Z., et al.. (2021). Increased incidence of chalazion associated with face mask wear during the COVID-19 pandemic. American Journal of Ophthalmology Case Reports. 22. 101032–101032. 22 indexed citations

14.

Ugradar, Shoaib, Lu Shi, Yao Wang, et al.. (2020). Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. Eye. 35(9). 2607–2612. 38 indexed citations

15.

Ugradar, Shoaib, et al.. (2020). Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease. British Journal of Ophthalmology. 106(2). 165–171. 49 indexed citations

16.

Bhattacharjee, Kasturi, et al.. (2020). Lower eyelid blepharoplasty: An overview. Indian Journal of Ophthalmology. 68(10). 2075–2075. 27 indexed citations

17.

Ugradar, Shoaib & Daniel B. Rootman. (2019). Quantification of optic nerve length and tortuosity in thyroid eye disease. Canadian Journal of Ophthalmology. 54(5). 611–614. 6 indexed citations

18.

Ramesh, Sathyadeepak, et al.. (2019). The Force Required to Inject a Column of Filler Through Facial Arteries. Dermatologic Surgery. 46(9). e32–e37. 10 indexed citations

19.

Ugradar, Shoaib, et al.. (2018). Management of graves myopathy. Journal of American Association for Pediatric Ophthalmology and Strabismus. 22(4). 256.e1–256.e9. 13 indexed citations

20.

Ugradar, Shoaib, et al.. (2016). Significance of Early Postoperative Eyelid Position on Late Postoperative Result in Müller’s Muscle Conjunctival Resection Surgery. Investigative Ophthalmology & Visual Science. 57(12). 718–718. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact